Quest Diagnostics Inc vs Trump Media and Technology Group Corp — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while Trump Media and Technology Group Corp trades at $9.54 (market cap $2.50B). The key difference: Quest Diagnostics Inc is far larger — about 9.1× Trump Media and Technology Group Corp's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals.
| DGX | DJT | |
|---|---|---|
Market Cap | $22.80B | $2.50B |
Sector | Health | Media |
52-Week High | $216.02 | $19.86 |
52-Week Low | $166.42 | $7.06 |
Enterprise Value | $28.82B | $2.45B |
Dividend Yield | 1.67% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
DJT trades at $8.52, down 0.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported minimal revenue of $3.68M in 2025 alongside a massive net loss of -$712.06M, reflecting severe profitability challenges. Recent news highlights a nearly 50% stock decline in 2026 and the cancellation of a Truth Social spin-off, while a merger with TAE Technologies aims to pivot toward nuclear fusion energy.
The outlook remains highly speculative, with the stock's meme-driven volatility and fundamental weaknesses posing significant risks. Investment opportunity hinges on successful execution of the TAE merger and fusion technology prospects, but persistent losses and high valuation ratios suggest substantial downside potential if growth fails to materialize.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →